Highlights
KLSE: GLOTEC (5220)       GLOBALTEC FORMATION BERHAD MAIN : Industrial Products
Last Price Today's Change   Day's Range   Trading Volume
0.39   +0.005 (1.30%)  0.385 - 0.39  168,900
Analyze this stock with MQ Trader system

Financials


Market Cap: 105 Million

Market Cap 105 Million
NOSH 269 Million

Latest Audited Result:  30-Jun-2020

Latest Audited Result: 30-Jun-2020
Announcement Date 30-Oct-2020
Next Audited Result: 30-Jun-2021
Est. Ann. Date: 30-Oct-2021
Est. Ann. Due Date: 27-Dec-2021

Latest Quarter:  30-Sep-2020 [#1]

Latest Quarter: 30-Sep-2020 [#1]
Announcement Date 27-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 27-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   893.06%  |    437.57%

Annual (Unaudited) ( EPS: 0.87, P/E: 44.73 )

Revenue | NP to SH 164,447  |  2,348
RPS | P/RPS 61.06 Cent  |  0.64
EPS | P/E | EY 0.87 Cent  |  44.73  |  2.24%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.89  |  0.44
YoY   112.15%
NP Margin | ROE -0.67%  |  0.98%
F.Y. | Ann. Date 30-Jun-2020  |  27-Aug-2020

T4Q Result ( EPS: 4.12, P/E: 9.47 )

Revenue | NP to SH 147,829  |  11,095
RPS | P/RPS 54.89 Cent  |  0.71
EPS | P/E | EY 4.12 Cent  |  9.47  |  10.56%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.91  |  0.43
QoQ | YoY   372.53%  |    160.70%
NP Margin | ROE 11.75%  |  4.52%
F.Y. | Ann. Date 30-Sep-2020  |  27-Nov-2020

Annualized Result ( EPS: 15.96, P/E: 2.44 )

Revenue | NP to SH 145,392  |  42,984
RPS | P/RPS 53.98 Cent  |  0.72
EPS | P/E | EY 15.96 Cent  |  2.44  |  40.92%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   1,730.66%  |    437.57%
NP Margin | ROE 55.81%  |  17.52%
F.Y. | Ann. Date 30-Sep-2020  |  27-Nov-2020




Show?  YoY % Horiz. %

Last 10 FY Result
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
Revenue 145,392 147,829 164,447 217,298 194,825 186,889 224,707 299,368 318,963 387,759 216,119 0 -
  YoY % -1.65% -10.11% -24.32% 11.53% 4.25% -16.83% -24.94% -6.14% -17.74% 79.42% 0.00% -
  Horiz. % 67.27% 68.40% 76.09% 100.55% 90.15% 86.48% 103.97% 138.52% 147.59% 179.42% 100.00% -
PBT 88,748 23,220 3,828 -40,958 -36,186 -14,095 -12,108 -38,062 -35,412 -14,383 14,933 0 -
  YoY % 282.20% 506.58% 109.35% -13.19% -156.73% -16.41% 68.19% -7.48% -146.21% -196.32% 0.00% -
  Horiz. % 594.31% 155.49% 25.63% -274.28% -242.32% -94.39% -81.08% -254.89% -237.14% -96.32% 100.00% -
Tax -7,600 -5,856 -4,933 -2,900 -2,919 -4,400 -9,028 -7,740 -1,965 -5,575 -2,176 0 -
  YoY % -29.78% -18.71% -70.10% 0.65% 33.66% 51.26% -16.64% -293.89% 64.75% -156.20% 0.00% -
  Horiz. % 349.26% 269.12% 226.70% 133.27% 134.15% 202.21% 414.89% 355.70% 90.30% 256.20% 100.00% -
NP 81,148 17,364 -1,105 -43,858 -39,105 -18,495 -21,136 -45,802 -37,377 -19,958 12,757 0 -
  YoY % 367.33% 1,671.40% 97.48% -12.15% -111.44% 12.50% 53.85% -22.54% -87.28% -256.45% 0.00% -
  Horiz. % 636.11% 136.11% -8.66% -343.80% -306.54% -144.98% -165.68% -359.03% -292.99% -156.45% 100.00% -
NP to SH 42,984 11,095 2,348 -19,322 -20,356 -9,560 -17,238 -41,297 -37,185 -19,999 13,075 0 -
  YoY % 287.42% 372.53% 112.15% 5.08% -112.93% 44.54% 58.26% -11.06% -85.93% -252.96% 0.00% -
  Horiz. % 328.75% 84.86% 17.96% -147.78% -155.69% -73.12% -131.84% -315.85% -284.40% -152.96% 100.00% -
Tax Rate 8.56 % 25.22 % 128.87 % - % - % - % - % - % - % - % 14.57 % - % -
  YoY % -66.06% -80.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % 58.75% 173.10% 884.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% -
Total Cost 64,244 130,465 165,552 261,156 233,930 205,384 245,843 345,170 356,340 407,717 203,362 0 -
  YoY % -50.76% -21.19% -36.61% 11.64% 13.90% -16.46% -28.78% -3.13% -12.60% 100.49% 0.00% -
  Horiz. % 31.59% 64.15% 81.41% 128.42% 115.03% 100.99% 120.89% 169.73% 175.22% 200.49% 100.00% -
Net Worth 245,353 245,353 238,680 233,298 247,559 274,468 281,276 311,068 348,098 384,191 164,491 - -
  YoY % 0.00% 2.80% 2.31% -5.76% -9.80% -2.42% -9.58% -10.64% -9.39% 133.56% 0.00% -
  Horiz. % 149.16% 149.16% 145.10% 141.83% 150.50% 166.86% 171.00% 189.11% 211.62% 233.56% 100.00% -
Dividend
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
Div - 0 - - - - - - - - - - -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
Div Payout % - % - % - % - % - % - % - % - % - % - % - % - % -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
Equity
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
Net Worth 245,353 245,353 238,680 233,298 247,559 274,468 281,276 311,068 348,098 384,191 164,491 - -
  YoY % 0.00% 2.80% 2.31% -5.76% -9.80% -2.42% -9.58% -10.64% -9.39% 133.56% 0.00% -
  Horiz. % 149.16% 149.16% 145.10% 141.83% 150.50% 166.86% 171.00% 189.11% 211.62% 233.56% 100.00% -
NOSH 269,323 269,323 269,086 269,086 5,381,737 5,381,737 5,307,096 5,363,246 5,355,362 5,262,894 2,108,870 - -
  YoY % 0.00% 0.09% 0.00% -95.00% 0.00% 1.41% -1.05% 0.15% 1.76% 149.56% 0.00% -
  Horiz. % 12.77% 12.77% 12.76% 12.76% 255.20% 255.20% 251.66% 254.32% 253.94% 249.56% 100.00% -
Ratio Analysis
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
NP Margin 55.81 % 11.75 % -0.67 % -20.18 % -20.07 % -9.90 % -9.41 % -15.30 % -11.72 % -5.15 % 5.90 % - % -
  YoY % 374.98% 1,853.73% 96.68% -0.55% -102.73% -5.21% 38.50% -30.55% -127.57% -187.29% 0.00% -
  Horiz. % 945.93% 199.15% -11.36% -342.03% -340.17% -167.80% -159.49% -259.32% -198.64% -87.29% 100.00% -
ROE 17.52 % 4.52 % 0.98 % -8.28 % -8.22 % -3.48 % -6.13 % -13.28 % -10.68 % -5.21 % 7.95 % - % -
  YoY % 287.61% 361.22% 111.84% -0.73% -136.21% 43.23% 53.84% -24.34% -104.99% -165.53% 0.00% -
  Horiz. % 220.38% 56.86% 12.33% -104.15% -103.40% -43.77% -77.11% -167.04% -134.34% -65.53% 100.00% -
Per Share
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
RPS 53.98 54.89 61.11 80.75 3.62 3.47 4.23 5.58 5.96 7.37 10.25 - -
  YoY % -1.66% -10.18% -24.32% 2,130.66% 4.32% -17.97% -24.19% -6.38% -19.13% -28.10% 0.00% -
  Horiz. % 526.63% 535.51% 596.20% 787.80% 35.32% 33.85% 41.27% 54.44% 58.15% 71.90% 100.00% -
EPS 15.96 4.12 0.87 -7.18 -0.38 -0.18 -0.32 -0.77 -0.70 -0.38 0.62 0.00 -
  YoY % 287.38% 373.56% 112.12% -1,789.47% -111.11% 43.75% 58.44% -10.00% -84.21% -161.29% 0.00% -
  Horiz. % 2,574.19% 664.52% 140.32% -1,158.06% -61.29% -29.03% -51.61% -124.19% -112.90% -61.29% 100.00% -
DPS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
NAPS 0.9110 0.9110 0.8870 0.8670 0.0460 0.0510 0.0530 0.0580 0.0650 0.0730 0.0780 0.0000 -
  YoY % 0.00% 2.71% 2.31% 1,784.78% -9.80% -3.77% -8.62% -10.77% -10.96% -6.41% 0.00% -
  Horiz. % 1,167.95% 1,167.95% 1,137.18% 1,111.54% 58.97% 65.38% 67.95% 74.36% 83.33% 93.59% 100.00% -
Adjusted Per Share Value based on latest NOSH - 269,323
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
RPS 53.98 54.89 61.06 80.68 72.34 69.39 83.43 111.16 118.43 143.98 80.25 - -
  YoY % -1.66% -10.10% -24.32% 11.53% 4.25% -16.83% -24.95% -6.14% -17.75% 79.41% 0.00% -
  Horiz. % 67.26% 68.40% 76.09% 100.54% 90.14% 86.47% 103.96% 138.52% 147.58% 179.41% 100.00% -
EPS 15.96 4.12 0.87 -7.17 -7.56 -3.55 -6.40 -15.33 -13.81 -7.43 4.85 0.00 -
  YoY % 287.38% 373.56% 112.13% 5.16% -112.96% 44.53% 58.25% -11.01% -85.87% -253.20% 0.00% -
  Horiz. % 329.07% 84.95% 17.94% -147.84% -155.88% -73.20% -131.96% -316.08% -284.74% -153.20% 100.00% -
DPS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
NAPS 0.9110 0.9110 0.8862 0.8662 0.9192 1.0191 1.0444 1.1550 1.2925 1.4265 0.6108 0.0000 -
  YoY % 0.00% 2.80% 2.31% -5.77% -9.80% -2.42% -9.58% -10.64% -9.39% 133.55% 0.00% -
  Horiz. % 149.15% 149.15% 145.09% 141.81% 150.49% 166.85% 170.99% 189.10% 211.61% 233.55% 100.00% -
Price Multiplier on Financial Quarter End Date
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
Date AQR T4Q 30/06/20 28/06/19 29/06/18 30/06/17 30/06/16 30/06/15 30/06/14 28/06/13 29/06/12 - -
Price 0.4100 0.4100 0.3900 0.4200 0.0500 0.0550 0.0450 0.0600 0.0600 0.0650 0.0900 0.0000 -
P/RPS 0.76 0.75 0.64 0.52 1.38 1.58 1.06 1.07 1.01 0.88 0.00 0.00 -
  YoY % 1.33% 17.19% 23.08% -62.32% -12.66% 49.06% -0.93% 5.94% 14.77% 0.00% 0.00% -
  Horiz. % 86.36% 85.23% 72.73% 59.09% 156.82% 179.55% 120.45% 121.59% 114.77% 100.00% - -
P/EPS 2.57 9.95 44.70 -5.85 -13.22 -30.96 -13.85 -7.79 -8.64 -17.11 0.00 0.00 -
  YoY % -74.17% -77.74% 864.10% 55.75% 57.30% -123.54% -77.79% 9.84% 49.50% 0.00% 0.00% -
  Horiz. % -15.02% -58.15% -261.25% 34.19% 77.26% 180.95% 80.95% 45.53% 50.50% 100.00% - -
EY 38.93 10.05 2.24 -17.10 -7.56 -3.23 -7.22 -12.83 -11.57 -5.85 0.00 0.00 -
  YoY % 287.36% 348.66% 113.10% -126.19% -134.06% 55.26% 43.73% -10.89% -97.78% 0.00% 0.00% -
  Horiz. % -665.47% -171.79% -38.29% 292.31% 129.23% 55.21% 123.42% 219.32% 197.78% 100.00% - -
DY 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
P/NAPS 0.45 0.45 0.44 0.48 1.09 1.08 0.85 1.03 0.92 0.89 1.17 0.00 -
  YoY % 0.00% 2.27% -8.33% -55.96% 0.93% 27.06% -17.48% 11.96% 3.37% -23.93% 0.00% -
  Horiz. % 38.46% 38.46% 37.61% 41.03% 93.16% 92.31% 72.65% 88.03% 78.63% 76.07% 100.00% -
Price Multiplier on Announcement Date
AQR T4Q 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 30/06/12 30/06/11 CAGR
Date AQR T4Q 27/08/20 30/08/19 28/08/18 28/08/17 26/08/16 27/08/15 21/08/14 28/08/13 30/08/12 - -
Price 0.3900 0.3900 0.4850 0.3750 0.0450 0.0500 0.0450 0.0450 0.1250 0.0600 0.0800 0.0000 -
P/RPS 0.72 0.71 0.79 0.46 1.24 1.44 1.06 0.81 2.10 0.81 0.00 0.00 -
  YoY % 1.41% -10.13% 71.74% -62.90% -13.89% 35.85% 30.86% -61.43% 159.26% 0.00% 0.00% -
  Horiz. % 88.89% 87.65% 97.53% 56.79% 153.09% 177.78% 130.86% 100.00% 259.26% 100.00% - -
P/EPS 2.44 9.47 55.58 -5.22 -11.90 -28.15 -13.85 -5.84 -18.00 -15.79 0.00 0.00 -
  YoY % -74.23% -82.96% 1,164.75% 56.13% 57.73% -103.25% -137.16% 67.56% -14.00% 0.00% 0.00% -
  Horiz. % -15.45% -59.97% -351.99% 33.06% 75.36% 178.28% 87.71% 36.99% 114.00% 100.00% - -
EY 40.92 10.56 1.80 -19.15 -8.41 -3.55 -7.22 -17.11 -5.55 -6.33 0.00 0.00 -
  YoY % 287.50% 486.67% 109.40% -127.71% -136.90% 50.83% 57.80% -208.29% 12.32% 0.00% 0.00% -
  Horiz. % -646.45% -166.82% -28.44% 302.53% 132.86% 56.08% 114.06% 270.30% 87.68% 100.00% - -
DY 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
P/NAPS 0.43 0.43 0.55 0.43 0.98 0.98 0.85 0.78 1.92 0.82 1.04 0.00 -
  YoY % 0.00% -21.82% 27.91% -56.12% 0.00% 15.29% 8.97% -59.38% 134.15% -21.15% 0.00% -
  Horiz. % 41.35% 41.35% 52.88% 41.35% 94.23% 94.23% 81.73% 75.00% 184.62% 78.85% 100.00% -

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock with T+7 trading account. Find out more.
  27 people like this.
 
pretty_life Wahh... look like going to fly high again... 0.600 can hit by today?
24/08/2020 11:24 AM
dompeilee Bought Glotec @ 42.5c at the open.
12/10/2020 9:44 AM
sotsot1986 http://news.seehua.com/?p=614056&fbclid=IwAR0yMC_0WkSMt-3rd1exDM19Vzhm6Go40cZy23SxIPO6iej6tM1av-hoaSs

Glotec join the vaccine troop?
12/10/2020 10:53 AM
asd88 finally UP
13/10/2020 9:30 AM
bombominvest 0.75 today glotec limit up oh, don pump over!
13/10/2020 9:46 AM
trader2investor come on halal vaccine!!
13/10/2020 9:50 AM
scenery bodoh lah, halal vaccines, dont tell me anybody will use pig oil to make vaccines. rubbish..
13/10/2020 9:53 AM
foriforu u tau apa tu halal ke? hanya pig tak halal? so funny la u . Everybody laugh 9 u HAHA
13/10/2020 10:05 AM
trader2investor why la the negative vibe. chill. lets hope this counter can fly even higher today
13/10/2020 10:07 AM
xuxu talk only also can up like this ? director cina cakap vaccine halal ...???? haha. but raise is chance to sell
13/10/2020 10:09 AM
mdfadly Auch that is ugly
13/10/2020 10:38 AM
abc123_2020 collect, will be Limit UP
13/10/2020 10:46 AM
abc123_2020 Once the Malaysian halal certification is obtained, the Chinese coronavirus vaccine can be used in an emergency
October 11, 2020

(Kuala Lumpur, 9th) The President of the Chinese President Tan Sri Wu Tianquan said that the coronavirus vaccine developed by China is currently in the third phase of clinical trials under the UN World Health Organization. Once it has passed the market and obtained my country’s halal certification After that, it can be emergency in our country.


He said that President Hua fully supports the government's emergency response to the introduction of Chinese vaccines. In this regard, we are also prepared to cooperate with the governments of Malaysia and China and relevant parties, in accordance with all necessary regulations and regulations, to assist relevant enterprises in docking to introduce vaccines to Malaysia.

Wu Tianquan is also the president of the Chinese Assembly Hall in Sabah. He recently communicated with the leadership of the agency’s chief executive, Dr. Akma Yusuf, at the headquarters of the Malaysian Clinical Research Institute (CRM) to understand the organization’s operating procedures. In a statement issued today, it said.

According to the agency, relevant preparations have been made to introduce Chinese vaccines.

Wu Tianquan said that President Hua is also actively contacting relevant Chinese parties, hoping to assist and coordinate the introduction of approved vaccines to Malaysia, and cooperate with all departments and institutions, including Malaysian clinical research institutions, to help my country connect with enterprises. Anti-epidemic work, especially in civilian epidemic prevention.

He described that the Malaysian Clinical Research Institute was established in 2012 on the recommendation of the Malaysian Clinical Research Center (CRC), mainly to assist the government in managing overseas clinical research and to promote important work such as clinical research in my country. It is also well regulated by the National Pharmaceutical Regulatory Agency (NPRA) and the Medical Research and Ethics Committee (MREC).


At the same time, Wu Tianquan, who is also the major shareholder and executive chairman of Elite Holdings Limited (GLOTEC, 5220, main board industrial stock), a company listed on the Kuala Lumpur Stock Exchange, said that the group's subsidiaries are also discussing participation in the project of introducing Chinese vaccines, hoping to help Give corporate feedback on the national anti-epidemic work.

He said that in particular, the country is currently facing the third wave of attacks, and many regions in the country are trapped in yellow and red zones. After the implementation of the state closure and cross-county ban, the government, enterprises and businesses, including the people, must work together. Cooperate, comprehensively prevent and fight the epidemic, so as to flatten the curve as soon as possible.

"This includes arrangements for the introduction of vaccines. We hope that vaccines can be approved for market as soon as possible to resolve the crisis."

He pointed out that the Chinese government, through the Ministry of Science, Technology and Innovation, is also responsible for consulting with relevant Chinese government departments and institutions, and deciding on cooperation and procurement plans for COVID-19 vaccines. According to Carey, Minister of Science and Arts, the third phase clinical trial data of COVID-19 vaccine is expected to be analyzed by the end of this year. The department, the Ministry of Health and the General Prosecutor's Office are discussing relevant legal affairs and procurement models.
13/10/2020 1:06 PM
abc123_2020 https://www.theedgemarkets.com/article/malaysia-have-priority-recipient-status-chinas-covid19-vaccine-under-development-says
13/10/2020 1:06 PM
abc123_2020 LIMIT UP today..oh yeahh
13/10/2020 2:40 PM
WY Chan glotec also in vaccine?
13/10/2020 2:54 PM
WY Chan belum sudah pump
13/10/2020 3:00 PM
slient No more house power
13/10/2020 3:01 PM
de_investor wil limit up soon
13/10/2020 5:10 PM
abc123_2020 Open gap up tomorrow, another vaccine player in progress
13/10/2020 11:17 PM
de_yangtulor ..towards limit up
14/10/2020 12:07 AM
Leon168 https://www.nst.com.my/news/nation/2020/10/632062/malaysia-may-get-covid-19-vaccine-year-end-%E2%80%93-pm

Glotec will fly like Phoenix to the Sky! Unlimited UP UP UP! Ini Kalilah! Hari Ini Lah!!!
14/10/2020 6:16 AM
Batman_Return http://news.seehua.com/?p=614056&fbclid=IwAR0yMC_0WkSMt-3rd1exDM19Vzhm6Go40cZy23SxIPO6iej6tM1av-hoaSs
14/10/2020 8:08 AM
de_investor in waiting...4 limit up..heheee
14/10/2020 8:54 AM
NewbieInvest Nope, it drops
14/10/2020 9:42 AM
asd88 No volume today, no power
14/10/2020 5:10 PM
Batman_Return Retracement. Tomorrow cont limit up
14/10/2020 7:56 PM
Keyman188 So naive newbies.....
14/10/2020 8:38 PM
limfly20 Market already so many Covid Vaccine stock, not easy to start now. Will wait to buy when there is announcement from the company, but will buy a little bit to try luck
15/10/2020 2:27 AM
Swoosh glotech also involve in vaccine meh?
16/10/2020 11:07 AM
limfly20 What Vaccine ? Please tell
16/10/2020 4:50 PM
asd88 https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3096882
16/10/2020 5:42 PM
BruceWayne91 http://news.seehua.com/?p=614056&fbclid=IwAR0yMC_0WkSMt-3rd1exDM19Vzhm6Go40cZy23SxIPO6iej6tM1av-hoaSs
Read the entire story
16/10/2020 9:18 PM
hasimdaud fake new
19/10/2020 9:52 AM
hasimdaud drop from 56.5 to 43.5 fake news
19/10/2020 10:01 AM
limfly20 Cut loss , wasting time here, if buy hwgb or solution / bintai already make some profit, all price up recently
19/10/2020 1:29 PM
Lee Chee Wee Near support 0.425 wt weak selling, will rebound soon. Stay tune.
19/10/2020 3:06 PM
asd88 Been in collection mode for awhile now
20/10/2020 1:32 PM
mansaham1972 Tq glotec kasi untung segera
27/10/2020 8:21 PM
maxstore769 main2 area MA20 ni
28/10/2020 3:44 PM
cccthierry http://www.globaltec.com.my/index.php/resources/
05/11/2020 4:05 PM
maxstore769 .................
06/11/2020 10:34 AM
awesome20 related to auto industry..should get benefited from Bauto, Drbhicom price movement
15/11/2020 4:23 PM
limfly20 Dead Water, Hopeless
16/11/2020 4:07 AM
pari57 He he he agree
16/11/2020 4:44 AM
jasonysk Rubbish counter
20/11/2020 7:52 PM
mrmeow Laggard vaccine?
23/11/2020 8:08 PM
BilisMasin Scam counter
26/11/2020 11:44 AM
mrmeow Monday limit up
27/11/2020 5:39 PM
dompeilee Great set of results!!! =)
27/11/2020 5:48 PM